UNSPSC 51102857: Hydrocortisone/oxytetracycline

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP350. This VA Drug Class (OP350) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL OPHTHALMIC.

UNSPSC 51102857 Hydrocortisone/oxytetracycline is a Commodity code that spans pharmaceutical products used in emergency response and public health supply chains, though recent state and local solicitations tagged under this code show limited direct alignment with the code's nominal scope. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical warehouse contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 for Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets under an Invitation for Bid process—products used for antibiotic treatment rather than the specific hydrocortisone/oxytetracycline combination the code names. Seminole County, Florida issued an IFB in June 2026 for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually, a procurement focused on overdose reversal and harm-reduction equipment that falls outside the code's pharmaceutical product scope. State health departments and county health authorities appear to be the primary issuing bodies under this code classification, using cooperative purchasing vehicles and piggyback arrangements to aggregate pharmaceutical supply contracts.

Activity appears concentrated in Florida and Illinois based on recent records. The Seminole County procurement specifies quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with vendors responsible for all shipping costs and required to maintain workers' compensation and commercial general liability insurance. The Illinois contract reflects a 12-month initial term with renewal options for years 2 and 3, with no specific set-aside or preference designations applied. The mismatch between the code's stated scope (hydrocortisone/oxytetracycline combination products) and the actual procurements posted under it (antibiotics, naloxone, drug deactivation systems) suggests this code may receive inconsistent tagging or that state procurement systems are applying it broadly to pharmaceutical and health-supply categories. Firms pursuing this code should verify commodity accuracy before investing in capture strategy.